The possibility of delayed immune-related responses implies that patients who experience progressive disease may benefit from treatment with immunotherapy beyond progression (TBP). Here we demonstrated that a substantial proportion of patients with non–small-cell lung cancer treated with nivolumab, who were clinically stable and judged to be eligible for TBP derive a significant survival benefit from TBP. TBP is feasible and safe, and reduction or stabilization of target lesions may occur when patients with non–small-cell lung cancer continue nivolumab after initial progression. Discontinuation of nivolumab based only on radiologic progression might be premature.

Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression

Grossi F.;
2019-01-01

Abstract

The possibility of delayed immune-related responses implies that patients who experience progressive disease may benefit from treatment with immunotherapy beyond progression (TBP). Here we demonstrated that a substantial proportion of patients with non–small-cell lung cancer treated with nivolumab, who were clinically stable and judged to be eligible for TBP derive a significant survival benefit from TBP. TBP is feasible and safe, and reduction or stabilization of target lesions may occur when patients with non–small-cell lung cancer continue nivolumab after initial progression. Discontinuation of nivolumab based only on radiologic progression might be premature.
2019
Nivolumab; NSCLC; Pseudoprogression; RECIST; Treatment beyond progression; Adult; Aged; Aged; 80 and over; Antineoplastic Agents; Immunological; Carcinoma; Non-Small-Cell Lung; Disease Progression; Female; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nivolumab; Retrospective Studies; Survival Analysis; Treatment Outcome; Withholding Treatment
Ricciuti, B.; Genova, C.; Bassanelli, M.; De Giglio, A.; Brambilla, M.; Metro, G.; Baglivo, S.; Dal Bello, M. G.; Ceribelli, A.; Grossi, F.; Chiari, R.
File in questo prodotto:
File Dimensione Formato  
Ricciuti nivolumab beyond PD.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: DRM non definito
Dimensione 747.83 kB
Formato Adobe PDF
747.83 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2118822
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 30
social impact